Literature DB >> 23436662

Assessment of baseline characteristics and risk factors among Emergency Department patients presenting with recent onset atrial fibrillation: a retrospective cohort study.

F Buccelletti1, S Di Somma, P Iacomini, A Galante, F Pugliese, F Alegiani, G Bertazzoni, D Marsiliani, A Carroccia, A Granato, G Calabrò, J M Legramante, G Zuccalà, F Franceschi.   

Abstract

BACKGROUND: The Cardioversion of Atrial Fibrillation in Emergency (CAFE) study was an observational, retrospective, multicenter study focusing on patients with recent onset atrial fibrillation (AF) seen in six different Emergency Departments (ED) of Rome, Italy. AIM: The aim of this study was to present the baseline characteristics and risk factors of the patients enrolled to the CAFE study.
MATERIALS AND METHODS: We retrospectively reviewed 3085 eligible patients diagnosed with recent onset AF in any of the EDs between January 2008 and December 2009. Inclusion criteria required documented ICD-9 primary discharge/admission diagnosis of AF in the ED and stable hemodynamic conditions at presentation (systolic blood pressure > 90 mmHg). Exclusion criteria were permanent AF or an ongoing acute coronary syndrome.
RESULTS: Median age was 71 years (interquartile ranges, 62-78 years) and 50.8% were men. Palpitations was the most common symptom at ED presentation and was present in 73.5% of the study subjects. Hypertension was the most prevalent comorbidity, affecting 59.3% of the patients evaluated, and the presence of previous episode(s) of AF was also common (52.3%). Regarding home treatment, the drugs most prescribed were antiplatelets (31.2%) and diuretics (25.2%). A CHADS2 score of 0 was found in 814 patients (26.4%), while a CHADS2 score of 1 was reported in 1114 patients (36.1%). Finally, a CHADS2 score ≥ 2 was reported in 1157 patients (37.5%).
CONCLUSIONS: The present study represents an important snapshot of demographics, comorbidities, risk factors and anticoagulation management about patients with recent onset AF. Disparities were noted in anticoagulation management, suggesting that this is still a main problem among patients with AF.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23436662

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  5 in total

1.  Clinical characteristics and one year outcomes in Chinese atrial fibrillation patients with stable coronary artery disease: a population-based study.

Authors:  Ying Bai; Jun Zhu; Yan-Min Yang; Yan Liang; Hui-Qiong Tan; Juan Wang; Bi Huang; Han Zhang; Xing-Hui Shao
Journal:  J Geriatr Cardiol       Date:  2016-08       Impact factor: 3.327

2.  Factors Associated With Psycho-Cognitive Functions in Patients With Persistent Pain After Surgery for Femoral Neck Fracture.

Authors:  Atsushi Kitayama; Mitsumasa Hida; Hidenobu Takami; Naoki Hirata; Yuko Deguchi; Kazuya Miyaguchi; Masako Nakazono; Rie Nakagawa; Noriyuki Fukumoto; Katsumi Hamaoka
Journal:  J Clin Med Res       Date:  2017-07-27

3.  The Potential Implication of the Autonomic Nervous System in Hepatocellular Carcinoma.

Authors:  Romain Parent; Yori Gidron; Fanny Lebossé; Thomas Decaens; Fabien Zoulim
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2019-04-11

4.  Using machine learning to investigate the relationship between domains of functioning and functional mobility in older adults.

Authors:  Keisuke Hirata; Makoto Suzuki; Naoki Iso; Takuhiro Okabe; Hiroshi Goto; Kilchoon Cho; Junichi Shimizu
Journal:  PLoS One       Date:  2021-02-11       Impact factor: 3.240

5.  Identification of acute myocardial infarction in patients with atrial fibrillation and chest pain with a contemporary sensitive troponin I assay.

Authors:  Christoph Liebetrau; Michael Weber; Stergios Tzikas; Lars Palapies; Helge Möllmann; Gerhard Pioro; Tanja Zeller; Andres Beiras-Fernandez; Christoph Bickel; Andreas M Zeiher; Karl J Lackner; Stephan Baldus; Holger M Nef; Stefan Blankenberg; Christian W Hamm; Thomas Münzel; Till Keller
Journal:  BMC Med       Date:  2015-07-27       Impact factor: 8.775

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.